DelveInsight’s, “Gastric Cancer Pipeline Insight 2023” report provides comprehensive insights about 230+ companies and 230+ pipeline drugs in the Gastric Cancer pipeline landscape. It covers the Gastric Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Gastric Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Gastric Cancer Pipeline Report

• DelveInsight’s Gastric Cancer pipeline report depicts a robust space with 230+ active players working to develop 230+ pipeline therapies for Gastric Cancer treatment.
• The leading companies working in the Gastric Cancer Market include Hutchison Medipharma Limited, EMD Serono, Sumitomo Pharma, Jiangsu HengRui Medicine Co., Ltd., LintonPharm Co., Ltd., Rapa Therapeutics LLC, Jiangsu HengRui Medicine Co., Ltd., Eli Lilly and Company, Janssen Pharmaceutical K.K., Hoffmann-La Roche, Novartis, Genentech, Exelixis, Bristol-Myers Squibb, Pieris Pharmaceuticals, Inc., Pfizer, Leap Therapeutics, CSPC ZhongQi Pharmaceutical, Ellipses Pharma, Merck Sharp & Dohme LLC, Amgen, Hanmi Pharmaceutical, Taiho Oncology, Inc., Merck KGaA, Shanghai Henlius Biotech, LianBio LLC, Chengdu Kanghong Biotech, AB Science, Maxinovel, GlaxoSmithKline, Hoffmann-La Roche, Bayer, Hutchison Medipharma Limited, and others.
• Promising Gastric Cancer Pipeline Therapies in the various stages of development include S-1/Cisplatin, FLX475, Pembrolizumab, Nivolumab, Oxaliplatin, Volitinib, Docetaxel, and others.
• November 2023: Ono Pharmaceuticals Co. Ltd. announced a study of Phase 2 & 3 clinical trials for ONO-4538 and Oxaliplatin. The purpose of study is to evaluate the efficacy and safety of ONO-4538 with chemotherapy in unresectable advanced or recurrent gastric cancer (including esophagogastric junction cancer) not previously treated with the first-line therapy. Part 1 is intended to evaluate the tolerability, safety, and efficacy of ONO-4538 in combination with SOX therapy (Tegafur / gimeracil / oteracil potassium + Oxaliplatin) or CapeOX therapy (Capecitabine + Oxaliplatin).
• November 2023: RemeGen Co. Ltd announced a study of Phase 3 clinical trials for RC48-ADC and Paclitaxel injection. This is a Phase III, randomized, multicenter, open-label clinical trial designed to compare RC48-ADC to physician-choice standard treatment in participants with human epidermal growth factor receptor 2 (HER2)-overexpression locally advanced or metastatic gastric cancer.

 

Request a sample and discover the recent advances in Gastric Cancer Treatment Drugs @ Gastric Cancer Pipeline Report

 

In the Gastric Cancer pipeline report, a detailed description of the drug is given which includes a mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Gastric Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Gastric Cancer Overview

Stomach cancer is cancer that starts anywhere inside the stomach or the stomach wall. It’s also called gastric cancer. Stomach cancer is more common in older people. Around 50 out of 100 cases (around 50%) occur in people aged 75 or over. It is more common in men than women. Many stomach cancers are linked to lifestyle or environmental factors, including diet. Stomach cancer is linked with a bacteria that lives in the stomach called Helicobacter pylori.

 

Find out more about Gastric Cancer Therapeutics Assessment @ Gastric Cancer Preclinical and Discovery Stage Products

 

Gastric Cancer Emerging Drugs Profile

• IBI308: Innovent Biologics
• HLX10: Henlix Biotech
• Pamiparib: BeiGene

 

Gastric Cancer Pipeline Therapeutics Assessment

There are approx. 230+ key companies which are developing the Gastric Cancer therapies. The Gastric Cancer companies which have their Gastric Cancer drug candidates in the most advanced stage, i.e. phase III include, Innovent Biologics.

 

DelveInsight’s Gastric Cancer Pipeline Report covers around 230+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

 

Gastric Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.

 

Gastric Cancer Pipeline Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

 

Learn more about the emerging Gastric Cancer Pipeline Therapies @ Gastric Cancer Clinical Trials Assessment

 

Scope of the Gastric Cancer Pipeline Report

• Coverage- Global
• Gastric Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Gastric Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Gastric Cancer Companies- Hutchison Medipharma Limited, EMD Serono, Sumitomo Pharma, Jiangsu HengRui Medicine Co., Ltd., LintonPharm Co.,Ltd., Rapa Therapeutics LLC, Jiangsu HengRui Medicine Co., Ltd., Eli Lilly and Company, Janssen Pharmaceutical K.K., Hoffmann-La Roche, Novartis, Genentech, Exelixis, Bristol-Myers Squibb, Pieris Pharmaceuticals, Inc., Pfizer, Leap Therapeutics, CSPC ZhongQi Pharmaceutical, Ellipses Pharma, Merck Sharp & Dohme LLC, Amgen, Hanmi Pharmaceutical, Taiho Oncology, Inc., Merck KGaA, Shanghai Henlius Biotech, LianBio LLC, Chengdu Kanghong Biotech, AB Science, Maxinovel, GlaxoSmithKline, Hoffmann-La Roche, Bayer, Hutchison Medipharma Limited, and others.
• Gastric Cancer Pipeline Therapies- S-1/Cisplatin, FLX475, Pembrolizumab, Nivolumab, Oxaliplatin, Volitinib, Docetaxel, and others.

 

Dive deep into rich insights for new drugs for Gastric Cancer Treatment, Visit @ Gastric Cancer Market Drivers and Barriers, and Future Perspective

 

Table of Content

1. Introduction
2. Executive Summary
3. Gastric Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Late Stage Products (Phase III)
7. IBI308: Innovent Biologics
8. Drug profiles in the detailed report…..
9. Mid Stage Products (Phase II)
10. Pamiparib: BeiGene
11. Drug profiles in the detailed report…..
12. Early Stage Products (Phase I)
13. HC 5404 FU: HiberCell
14. Drug profiles in the detailed report…..
15. Preclinical and Discovery Stage Products
16. PolyPEPI 1311: Treos Bio
17. Drug profiles in the detailed report…..
18. Inactive Products
19. Gastric Cancer Key Companies
20. Gastric Cancer Key Products
21. Gastric Cancer- Unmet Needs
22. Gastric Cancer- Market Drivers and Barriers
23. Gastric Cancer- Future Perspectives and Conclusion
24. Gastric Cancer Analyst Views
25. Gastric Cancer Key Companies
26. Appendix

 

For further information on the Gastric Cancer Pipeline therapeutics, reach out to Gastric Cancer Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/ascites-market